Ambrx Biopharma Inc.
AMAM
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.77B
Close$
Share Statistics
| Market cap | $1.77 Billion |
|---|---|
| Enterprise Value | $1.56 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.02 |
| Beta | -2.36 |
| Outstanding Shares | 62,250,431 |
Return
| Return on Equity | -28.62% |
|---|---|
| Return on Assets | -25.55% |
| Return on Invested Capital | -27.95% |
Valuation & Multiples
| P/E Ratio | -13.86 |
|---|---|
| PEG | -18.87 |
| Price to Sales | - |
| Price to Book Ratio | 9.33 |
| Enterprise Value to Revenue | 452.18 |
| Enterprise Value to EBIT | -22.01 |
| Enterprise Value to Net Income | -23 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Ambrx Biopharma Inc
Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, ta...